iBio, Inc.
IBIOdata completeness 88%16 fiscal years on fileData notes: no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'dividendsPaid'
iBio, Inc. earns about -156% on equity, but has diluted owners by 1093% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Revenue | $1.88M1 | $02 | $225,0003 | $400,0004 | $100,0004 |
| Net income | −$50.3M5 | −$65M6 | −$24.9M7 | −$18.4M8 | −$33M8 |
| Operating cash flow | −$37.5M9 | −$30.4M10 | −$18.6M11 | −$15.3M12 | −$23.2M12 |
| Capital expenditure | $7.33M13 | $5.74M14 | $210,00015 | $16,00016 | $578,00016 |
| Free cash flow (derived) | −$44.8M9 | −$36.2M10 | −$18.8M11 | −$15.3M12 | −$23.8M12 |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $22.7M17 | $4.3M18 | $14.2M19 | $8.58M20 | $56.4M20 |
| Diluted shares | 8.7M | 612,000 | 3.8M | 10.5M | 104.1M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $8.24 of net worth that earned you −$3.18 and generated −$2.29 of cash last year.
It earned an average -156% on equity over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 1093% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2022-06-30 · accession 0001420720-23-000045 (Revenues)
- 10-K/A · period ending 2023-06-30 · accession 0001420720-24-000041 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-06-30 · accession 0001558370-25-011888 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2025-06-30 · accession 0001420720-26-000020 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-06-30 · accession 0001420720-22-000064 (NetIncomeLoss)
- 10-K/A · period ending 2023-06-30 · accession 0001420720-24-000041 (NetIncomeLoss)
- 10-K · period ending 2024-06-30 · accession 0001558370-25-011888 (NetIncomeLoss)
- 10-K · period ending 2025-06-30 · accession 0001420720-26-000020 (NetIncomeLoss)
- 10-K · period ending 2022-06-30 · accession 0001420720-23-000045 (NetCashProvidedByUsedInOperatingActivities)
- 10-K/A · period ending 2023-06-30 · accession 0001420720-24-000041 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-06-30 · accession 0001558370-25-011888 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2025-06-30 · accession 0001420720-26-000020 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-06-30 · accession 0001420720-23-000045 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K/A · period ending 2023-06-30 · accession 0001420720-24-000041 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-06-30 · accession 0001558370-25-011888 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2025-06-30 · accession 0001420720-26-000020 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-06-30 · accession 0001420720-23-000045 (CashAndCashEquivalentsAtCarryingValue)
- 10-K/A · period ending 2023-06-30 · accession 0001420720-24-000041 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-06-30 · accession 0001558370-25-011888 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2025-06-30 · accession 0001420720-26-000020 (CashAndCashEquivalentsAtCarryingValue)